Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C.

Authors :: Chapko MK
Yee HS
Monto A
Dominitz JA
Source :: Vaccine [Vaccine] 2010 Feb 17; Vol. 28 (7), pp. 1726-31. Date of Electronic Publication: 2009 Dec 29.
Publication Year :: 2010
Abstract: The incidence of hepatitis A infection in the United States has decreased dramatically in recent years because of childhood immunization programs. A decision analysis of the cost-effectiveness of hepatitis A vaccination for adults with hepatitis C was conducted. No vaccination strategy is cost-effective for adults with hepatitis C using the recent lower anticipated hepatitis A incidence, private sector costs, and a cost-effectiveness criterion of $100,000/QALY. Vaccination is cost-effective only for individuals who have cleared the hepatitis C virus when Department of Veterans Affairs costs are used. The recommendation to vaccinate adults with hepatitis C against hepatitis A should be reconsidered.<br /> (Published by Elsevier Ltd.)

Subjects :: Cost-Benefit Analysis
Hepatitis A epidemiology
Hepatitis C, Chronic complications
Humans
Immunization Programs economics
Incidence
Markov Chains
Middle Aged
Quality-Adjusted Life Years
Hepatitis A prevention & control
Hepatitis A Vaccines economics

Full Text Access

Tools